{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T07:08:47Z","timestamp":1772435327153,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,28]]},"DOI":"10.7759\/cureus.19976","type":"journal-article","created":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T07:57:46Z","timestamp":1638172666000},"source":"Crossref","is-referenced-by-count":2,"title":["Comparative Safety and Efficacy of Remdesivir Versus Remdesivir Plus Convalescent Plasma Therapy (CPT) and the Effect of Timing of Initiation of Remdesivir in COVID-19 Patients: An Observational Study From North East India"],"prefix":"10.7759","author":[{"given":"Dibya J","family":"Sharma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aparajita","family":"Deb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phulen","family":"Sarma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bipadabhanjan","family":"Mallick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prithwiraj","family":"Bhattacharjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.4103\/ijp.IJP_338_20","article-title":"Update on the target structures of SARS-CoV-2: a systematic review","volume":"52","author":"Prajapat M","year":"2020","unstructured":"Prajapat M, Sarma P, Shekhar N, et al.. Update on the target structures of SARS-CoV-2: a systematic review. Indian J Pharmacol. 2020, 52:142-9. 10.4103\/ijp.IJP_338_20","journal-title":"Indian J Pharmacol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30186-0","article-title":"Emerging understandings of 2019-nCoV","volume":"395","author":"The Lancet","year":"2020","unstructured":"The Lancet. Emerging understandings of 2019-nCoV. Lancet. 2020, 395:311. 10.1016\/S0140-6736(20)30186-0","journal-title":"Lancet"},{"key":"ref3","article-title":"Ocular manifestations and tear or conjunctival swab PCR positivity for 2019-nCoV in patients with COVID- 19: a systematic review and meta-analysis","author":"Sarma P","year":"2020","unstructured":"Sarma P, Kaur H, Kaur H, et al.. Ocular manifestations and tear or conjunctival swab PCR positivity for 2019-nCoV in patients with COVID- 19: a systematic review and meta-analysis. SSRN. 2020, 3566161.","journal-title":"SSRN"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s41927-020-00165-0","article-title":"Rheumatic manifestations of COVID-19: a systematic review and meta-analysis","volume":"4","author":"Ciaffi J","year":"2020","unstructured":"Ciaffi J, Meliconi R, Ruscitti P, Berardicurti O, Giacomelli R, Ursini F. Rheumatic manifestations of COVID-19: a systematic review and meta-analysis. BMC Rheumatol. 2020, 4:65. 10.1186\/s41927-020-00165-0","journal-title":"BMC Rheumatol"},{"key":"ref5","unstructured":"Clinical Management Protocol. COVID-19 Version 5, Dated 03.07.20. https:\/\/www.mohfw.gov.in\/pdf\/UpdatedClinicalManagementProtocolforCOVID19dated03072020.pdf."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25735","article-title":"Clinical characteristics of hospitalized patients with SARS-CoV-2 infection: a single arm meta-analysis","volume":"92","author":"Sun P","year":"2020","unstructured":"Sun P, Qie S, Liu Z, Ren J, Li K, Xi J. Clinical characteristics of hospitalized patients with SARS-CoV-2 infection: a single arm meta-analysis. J Med Virol. 2020, 92:612-7. 10.1002\/jmv.25735","journal-title":"J Med Virol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1101\/2020.04.19.20062117","article-title":"Clinical characteristics of hospitalized Covid-19 patients in New York City","author":"Paranjpe I","year":"2020","unstructured":"Paranjpe I, Russak AJ, De Freitas JK, et al.. Clinical characteristics of hospitalized Covid-19 patients in New York City. medRxiv : the preprint server for health sciences. 2020, 2020.04.19.20062117. 10.1101\/2020.04.19.20062117","journal-title":"medRxiv : the preprint server for health sciences"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.4103\/ijp.ijp_1146_20","article-title":"Efficacy and safety of steroid therapy in COVID-19: a rapid systematic review and meta-analysis","volume":"52","author":"Sarma P","year":"2020","unstructured":"Sarma P, Bhattacharyya A, Kaur H, et al.. Efficacy and safety of steroid therapy in COVID-19: a rapid systematic review and meta-analysis. Indian J Pharmacol. 2020, 52:535-50. 10.4103\/ijp.ijp_1146_20","journal-title":"Indian J Pharmacol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.173926","article-title":"Remdesivir for treatment of COVID-19; an updated systematic review and meta-analysis","volume":"897","author":"Rezagholizadeh A","year":"2021","unstructured":"Rezagholizadeh A, Khiali S, Sarbakhsh P, Entezari-Maleki T. Remdesivir for treatment of COVID-19; an updated systematic review and meta-analysis. Eur J Pharmacol. 2021, 897:173926. 10.1016\/j.ejphar.2021.173926","journal-title":"Eur J Pharmacol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25898","article-title":"Virological and clinical cure in COVID-19 patients treated with hydroxychloroquine: a systematic review and meta-analysis","volume":"92","author":"Sarma P","year":"2020","unstructured":"Sarma P, Kaur H, Kumar H, et al.. Virological and clinical cure in COVID-19 patients treated with hydroxychloroquine: a systematic review and meta-analysis. J Med Virol. 2020, 92:776-85. 10.1002\/jmv.25898","journal-title":"J Med Virol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.7326\/M20-4207","article-title":"Hydroxychloroquine in nonhospitalized adults with early COVID-19: a randomized trial","volume":"173","author":"Skipper CP","year":"2020","unstructured":"Skipper CP, Pastick KA, Engen NW, et al.. Hydroxychloroquine in nonhospitalized adults with early COVID-19: a randomized trial. Ann Intern Med. 2020, 173:623-31. 10.7326\/M20-4207","journal-title":"Ann Intern Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.7326\/L21-0001","article-title":"Hydroxychloroquine in nonhospitalized adults with early COVID-19","volume":"174","author":"Bhattacharyya A","year":"2021","unstructured":"Bhattacharyya A, Sarma P, Kaur H, Medhi B. Hydroxychloroquine in nonhospitalized adults with early COVID-19. Ann Intern Med. 2021, 174:434. 10.7326\/L21-0001","journal-title":"Ann Intern Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.4103\/ijp.ijp_998_20","article-title":"Systematic review and meta-analysis of effectiveness and safety of favipiravir in the management of novel coronavirus (COVID-19) patients","volume":"52","author":"Prakash A","year":"2020","unstructured":"Prakash A, Singh H, Kaur H, et al.. Systematic review and meta-analysis of effectiveness and safety of favipiravir in the management of novel coronavirus (COVID-19) patients. Indian J Pharmacol. 2020, 52:414-21. 10.4103\/ijp.ijp_998_20","journal-title":"Indian J Pharmacol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s43440-020-00195-y","article-title":"Ivermectin as a potential drug for treatment of COVID-19: an in-sync review with clinical and computational attributes","volume":"73","author":"Kaur H","year":"2021","unstructured":"Kaur H, Shekhar N, Sharma S, Sarma P, Prakash A, Medhi B. Ivermectin as a potential drug for treatment of COVID-19: an in-sync review with clinical and computational attributes. Pharmacol Rep. 2021, 73:736-49. 10.1007\/s43440-020-00195-y","journal-title":"Pharmacol Rep"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3939","article-title":"Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)","volume":"371","author":"Agarwal A","year":"2020","unstructured":"Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar T, Malhotra P. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial). BMJ. 2020, 371:m3939. 10.1136\/bmj.m3939","journal-title":"BMJ"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.4103\/ijp.IJP_115_20","article-title":"Drug targets for corona virus: a systematic review","volume":"52","author":"Prajapat M","year":"2020","unstructured":"Prajapat M, Sarma P, Shekhar N, et al.. Drug targets for corona virus: a systematic review. Indian J Pharmacol. 2020, 52:56-65. 10.4103\/ijp.IJP_115_20","journal-title":"Indian J Pharmacol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2021.110539","article-title":"Folic acid as placebo in controlled clinical trials of hydroxychloroquine prophylaxis in COVID-19: is it scientifically justifiable?","volume":"149","author":"Kaur H","year":"2021","unstructured":"Kaur H, Sarma P, Bhattacharyya A, Prajapat M, Kumar S, Prakash A, Medhi B. Folic acid as placebo in controlled clinical trials of hydroxychloroquine prophylaxis in COVID-19: is it scientifically justifiable?. Med Hypotheses. 2021, 149:110539. 10.1016\/j.mehy.2021.110539","journal-title":"Med Hypotheses"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s11886-020-01328-8","article-title":"The role of anticoagulation in COVID-19-induced hypercoagulability","volume":"22","author":"Rico-Mesa JS","year":"2020","unstructured":"Rico-Mesa JS, Rosas D, Ahmadian-Tehrani A, White A, Anderson AS, Chilton R. The role of anticoagulation in COVID-19-induced hypercoagulability. Curr Cardiol Rep. 2020, 22:53. 10.1007\/s11886-020-01328-8","journal-title":"Curr Cardiol Rep"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang M","year":"2020","unstructured":"Wang M, Cao R, Zhang L, et al.. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020, 30:269-71. 10.1038\/s41422-020-0282-0","journal-title":"Cell Res"},{"key":"ref20","unstructured":"COVID-19 update. FDA broadens emergency use authorization for Veklury (remdesivir) to include all hospitalized patients for treatment of COVID-19. (2020). Accessed: 29 November 2021: https:\/\/www.fda.gov\/news-events\/press-announcements\/covid-19-update-fda-broadens-emergency-use-authorization-veklury-...."},{"key":"ref21","unstructured":"FDA issues emergency use authorization for convalescent plasma as potential promising COVID-19 treatment, another achievement in administration\u2019s fight against pandemic. (2021). Accessed. 26 April 2021: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-issues-emergency-use-authorization-convalescent-plasma-potent...."},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang Y","year":"2020","unstructured":"Wang Y, Zhang D, Du G, et al.. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020, 395:1569-78. 10.1016\/S0140-6736(20)31022-9","journal-title":"Lancet"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of Covid-19 - final report","volume":"383","author":"Beigel JH","year":"2020","unstructured":"Beigel JH, Tomashek KM, Dodd LE, et al.. Remdesivir for the treatment of Covid-19 - final report. N Engl J Med. 2020, 383:1813-26. 10.1056\/NEJMoa2007764","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.16349","article-title":"Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial","volume":"324","author":"Spinner CD","year":"2020","unstructured":"Spinner CD, Gottlieb RL, Criner GJ, et al.. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA. 2020, 324:1048-57. 10.1001\/jama.2020.16349","journal-title":"JAMA"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2023184","article-title":"Repurposed antiviral drugs for COVID-19 - interim WHO solidarity trial results","volume":"384","author":"Pan H","year":"2021","unstructured":"Pan H, Peto R, Henao-Restrepo AM, et al.. Repurposed antiviral drugs for COVID-19 - interim WHO solidarity trial results. N Engl J Med. 2021, 384:497-511. 10.1056\/NEJMoa2023184","journal-title":"N Engl J Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2031994","article-title":"Baricitinib plus remdesivir for hospitalized adults with Covid-19","volume":"384","author":"Kalil AC","year":"2021","unstructured":"Kalil AC, Patterson TF, Mehta AK, et al.. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med. 2021, 384:795-807. 10.1056\/NEJMoa2031994","journal-title":"N Engl J Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2015301","article-title":"Remdesivir for 5 or 10 days in patients with severe Covid-19","volume":"383","author":"Goldman JD","year":"2020","unstructured":"Goldman JD, Lye DC, Hui DS, et al.. Remdesivir for 5 or 10 days in patients with severe Covid-19. N Engl J Med. 2020, 383:1827-37. 10.1056\/NEJMoa2015301","journal-title":"N Engl J Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2021.02.092","article-title":"A shorter symptom onset to remdesivir treatment (SORT) interval is associated with a lower mortality in moderate-to-severe COVID-19: a real-world analysis","volume":"106","author":"Mehta RM","year":"2021","unstructured":"Mehta RM, Bansal S, Bysani S, Kalpakam H. A shorter symptom onset to remdesivir treatment (SORT) interval is associated with a lower mortality in moderate-to-severe COVID-19: a real-world analysis. Int J Infect Dis. 2021, 106:71-7. 10.1016\/j.ijid.2021.02.092","journal-title":"Int J Infect Dis"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(20)30152-2","article-title":"Practical recommendations for the management of diabetes in patients with COVID-19","volume":"8","author":"Bornstein SR","year":"2020","unstructured":"Bornstein SR, Rubino F, Khunti K, et al.. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol. 2020, 8:546-50. 10.1016\/S2213-8587(20)30152-2","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref30","unstructured":"Guidelines on clinical management of severe acute respiratory illness (SARI) in suspect\/confirmed novel coronavirus (nCoV) cases. (2020). Accessed. 29 November 2021: https:\/\/ncdc.gov.in\/WriteReadData\/l892s\/96997299691580715786.pdf."},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013600.pub2","article-title":"Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review","volume":"7","author":"Piechotta V","year":"2020","unstructured":"Piechotta V, Chai KL, Valk SJ, et al.. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Cochrane Database Syst Rev. 2020, 7:CD013600. 10.1002\/14651858.CD013600.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.3071","article-title":"Comparison of time to clinical improvement with vs without remdesivir treatment in hospitalized patients with COVID-19","volume":"4","author":"Garibaldi BT","year":"2021","unstructured":"Garibaldi BT, Wang K, Robinson ML, et al.. Comparison of time to clinical improvement with vs without remdesivir treatment in hospitalized patients with COVID-19. JAMA Netw Open. 2021, 4:e213071. 10.1001\/jamanetworkopen.2021.3071","journal-title":"JAMA Netw Open"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/74112-comparative-safety-and-efficacy-of-remdesivir-versus-remdesivir-plus-convalescent-plasma-therapy-cpt-and-the-effect-of-timing-of-initiation-of-remdesivir-in-covid-19-patients-an-observational-study-from-north-east-india","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:32:13Z","timestamp":1707507133000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/74112-comparative-safety-and-efficacy-of-remdesivir-versus-remdesivir-plus-convalescent-plasma-therapy-cpt-and-the-effect-of-timing-of-initiation-of-remdesivir-in-covid-19-patients-an-observational-study-from-north-east-india"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,28]]},"references-count":32,"URL":"https:\/\/doi.org\/10.7759\/cureus.19976","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11,28]]}}}